Ascendiant Capital Maintains Buy on Lucid Diagnostics, Lowers Price Target to $7.25
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital's analyst Edward Woo maintains a Buy rating on Lucid Diagnostics but lowers the price target from $7.5 to $7.25.
September 10, 2024 | 9:41 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ascendiant Capital's analyst Edward Woo maintains a Buy rating on Lucid Diagnostics but lowers the price target from $7.5 to $7.25.
The analyst's decision to maintain a Buy rating suggests confidence in Lucid Diagnostics' potential, but the slight reduction in the price target indicates a more cautious outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100